At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 131 enrolled
Drug / intervention
Eptinezumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Interventional, Open-label, Fixed-dose Multiple Administration Study to Evaluate Long-term Treatment With Eptinezumab in Patients With Chronic Cluster Headache
In Brief
A Phase 3 clinical trial evaluating Eptinezumab for Chronic Cluster Headache. Completed, enrolled 131 participants across 31 sites in 9 countries.
Detailed Summary
The main goal of this trial is to inform about long-term safety and tolerability of eptinezumab in participants with chronic cluster headache.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Cluster Headache
CountriesDenmark, Finland, France, Germany, Italy, Netherlands, Spain, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20222023202420252026
Enrollment StartSep 2021
First PostedOct 2021
Primary CompletionJun 2023
TodayJul 2026
First PostedOct 1, 2021
Enrollment StartSep 17, 2021
Primary CompletionJun 29, 2023
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 4.8 years ago
Interventions
Eptinezumabdrug
Eptinezumab will be administered per schedule specified in the arm description.